By Counterforce Health Team in Arikayce (amikacin liposome inhalation) —

How to Get Arikayce (Amikacin Liposome Inhalation) Covered by Blue Cross Blue Shield in Virginia: Complete Guide to Prior Authorization and Appeals

Answer Box: Getting Arikayce Covered by Blue Cross Blue Shield in Virginia

Arikayce (amikacin liposome inhalation) requires prior authorization from Blue Cross Blue Shield in Virginia for MAC lung disease. To get coverage, you need documented refractory MAC after 6+ months of standard multidrug therapy with persistent positive cultures. Submit your PA request through Anthem's provider portal or fax to 844-512-7020. If denied, Virginia offers external review through the State Corporation Commission within 120 days, with decisions in 45 days (72 hours if expedited).

First step today: Contact your prescriber to gather documentation of your 6-month treatment history and current culture results.

Table of Contents

  1. Coverage Basics: Is Arikayce Covered?
  2. Prior Authorization Process
  3. Timeline and Urgency
  4. Medical Necessity Criteria
  5. Costs and Financial Assistance
  6. Denials and Appeals
  7. Renewals and Continuing Coverage
  8. Specialty Pharmacy Requirements
  9. Troubleshooting Common Issues
  10. Frequently Asked Questions

Coverage Basics: Is Arikayce Covered?

Yes, Arikayce is covered by Blue Cross Blue Shield plans in Virginia, but requires prior authorization. Anthem Blue Cross Blue Shield Virginia lists Arikayce as requiring PA for all members.

Which Plans Cover Arikayce?

Plan Type Coverage Status Special Requirements
Commercial PPO/HMO Covered with PA Medical necessity review
Medicare Advantage Varies by plan Check specific formulary
Medicaid Managed Care Covered with PA Additional state criteria may apply
Note: Coverage details may vary between different Blue Cross Blue Shield plans operating in Virginia. Always verify with your specific plan.

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Gather Required Documentation (Patient/Clinic)
    • Complete medical records showing MAC diagnosis
    • Documentation of 6+ months standard therapy
    • Recent sputum culture results
    • Current medication list and dosing
  2. Complete PA Form (Prescriber)
    • Submit via Availity Essentials portal or Interactive Care Reviewer (ICR)
    • Alternative: Fax completed form to 844-512-7020
    • Expected timeline: 3-5 business days
  3. Include Medical Necessity Letter (Prescriber)
    • Document refractory MAC status
    • Reference current treatment guidelines
    • Justify combination therapy approach
  4. Track Application Status (Patient/Clinic)
    • Monitor through provider portal
    • Contact Provider Services at 800-901-0020 for updates

Timeline and Urgency

Standard Processing Times

  • Initial PA Decision: 3-5 business days
  • Expedited Review: 24-72 hours (with clinical justification)
  • Appeal Response: 15-30 days for internal appeals
  • External Review: 45 days (72 hours if expedited)

When to Request Expedited Review

Request expedited processing if:

  • Patient's condition is rapidly deteriorating
  • Delay could cause serious harm
  • Current therapy is failing and immediate intervention needed
Tip: Have your physician document the urgency in clinical terms that insurance reviewers understand.

Medical Necessity Criteria

Clinician Corner: Medical Necessity Requirements

Arikayce approval requires meeting strict FDA-approved criteria:

✅ Required Documentation:

  • Confirmed MAC lung disease diagnosis (radiographic + microbiologic evidence)
  • Minimum 6 consecutive months of guideline-based multidrug therapy
  • Persistent positive sputum cultures after 6-month treatment period
  • Use as part of combination therapy (not monotherapy)
  • Prescriber attestation of medical necessity

❌ Common Approval Barriers:

  • Less than 6 months of prior therapy
  • Off-label use for initial MAC treatment
  • Monotherapy without background regimen
  • Missing culture documentation
  • Amikacin resistance (MIC >64 mcg/mL)

Key Clinical Guidelines

The 2020 ATS/ERS/ESCMID/IDSA guidelines strongly recommend adding Arikayce for patients meeting refractory criteria. Include this reference in your medical necessity letter.

Costs and Financial Assistance

Understanding Your Costs

Arikayce is typically classified as a specialty medication, placing it on higher formulary tiers with significant cost-sharing:

  • Tier 4-5 Specialty: 20-50% coinsurance
  • Monthly costs: Can range from $500-$3,000+ depending on plan
  • Annual out-of-pocket maximum: Provides cost protection

Financial Assistance Options

  1. Manufacturer Support
  2. Copay Waiver Requests
    • Submit exception request through BCBS member portal
    • Include financial hardship documentation
  3. Non-Profit Assistance
    • Patient advocacy organizations for rare lung diseases
    • State pharmaceutical assistance programs

Denials and Appeals

Appeals Playbook for Blue Cross Blue Shield in Virginia

Level 1: Internal Appeal

  • Timeline: Must file within 180 days of denial
  • Decision time: 15-30 days
  • How to file: Member services phone line or written request
  • Required: Copy of denial letter, additional clinical evidence

Level 2: External Review (Virginia SCC)

  • Timeline: File within 120 days of final internal denial
  • Decision time: 45 days standard, 72 hours expedited
  • How to file: Form 216-A to Virginia SCC
  • Cost: Free to Virginia residents
  • Binding: Decision is final and binding on insurer

Common Denial Reasons & Solutions

Denial Reason Documentation to Include Success Strategy
"Not medically necessary" Clinical guidelines, treatment history Emphasize refractory status per FDA label
"Insufficient trial duration" Detailed medication timeline Document exact dates of 6+ month therapy
"Missing culture results" Lab reports with dates Include pre/post treatment cultures
"Not formulary preferred" Step therapy documentation Show failures/contraindications to alternatives
From our advocates: "We've seen Virginia external reviews overturn about 60% of specialty drug denials when patients provide comprehensive clinical documentation and reference current treatment guidelines. The key is showing you've truly met the FDA's refractory criteria with dated, detailed records."

Renewals and Continuing Coverage

When to Re-authorize

  • Initial approval: Typically 12 months
  • Renewal timing: Submit 30-60 days before expiration
  • Required updates: Current culture results, treatment response, tolerability assessment

Continuation Criteria

For renewal approval, document:

  • Ongoing combination therapy compliance
  • Clinical response or stability
  • Absence of prohibitive side effects
  • Ongoing medical necessity

Specialty Pharmacy Requirements

Why was my prescription transferred? Arikayce requires specialty pharmacy dispensing due to:

  • Complex storage requirements
  • Patient education needs
  • Monitoring requirements
  • Insurance contract requirements

Virginia Specialty Pharmacy Network

Most BCBS Virginia plans contract with specific specialty pharmacies. Contact member services at the number on your ID card to confirm your plan's preferred network.

Troubleshooting Common Issues

Portal Problems

  • Portal down? Call Provider Services at 800-901-0020
  • Missing forms? Download from Anthem provider resources
  • Login issues? Contact Availity support directly

Documentation Issues

  • Missing records? Request from all treating physicians
  • Culture reports unclear? Ask lab for detailed sensitivity results
  • Timeline gaps? Pharmacy records can fill medication history gaps

Frequently Asked Questions

Q: How long does BCBS prior authorization take in Virginia? A: Standard PA decisions take 3-5 business days. Expedited reviews (with clinical justification) can be completed in 24-72 hours.

Q: What if Arikayce is non-formulary on my plan? A: You can request a formulary exception by demonstrating medical necessity and providing documentation that preferred alternatives aren't appropriate.

Q: Can I request an expedited appeal if denied? A: Yes, if your physician certifies that delays could seriously jeopardize your health. Virginia allows expedited external review with 72-hour decisions.

Q: Does step therapy apply to Arikayce? A: The 6-month refractory requirement essentially serves as step therapy, requiring documented failure of standard MAC treatment.

Q: What if I move to Virginia from another state? A: Your new Virginia BCBS plan will require fresh prior authorization. Gather all documentation from your previous treatment.

Q: Who can help if I'm having trouble with the process? A: Contact Virginia's Bureau of Insurance Consumer Services at 1-877-310-6560 for assistance with insurance issues.

When to Escalate

Contact Virginia regulators if you experience:

  • Unreasonable delays beyond stated timelines
  • Procedural violations in the appeals process
  • Discrimination or unfair treatment

Virginia State Corporation Commission Bureau of Insurance

About Coverage Appeals: Counterforce Health helps patients, clinicians, and specialty pharmacies get prescription drugs approved by turning insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned with payer requirements, pulling appropriate clinical evidence and regulatory citations to support coverage requests.

For complex denials or appeals, consider working with coverage advocacy services like Counterforce Health that specialize in insurance approval strategies and understand payer-specific requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare provider and insurance plan directly for coverage determinations. For assistance with insurance issues in Virginia, contact the State Corporation Commission Bureau of Insurance at 1-877-310-6560.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.